Drug intelligence / Profile preview

anti-TIM3 antibody

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal, Subcutaneous

Overview

Anti-TIM3 refers to an antibody designed to target T-cell immunoglobulin and mucin domain-containing protein 3 (TIM3), an immune checkpoint protein. It is being developed as an oncology drug, with Bristol-Myers Squibb collaborating with Halozyme to create a subcutaneous formulation using the ENHANZE® technology for more convenient administration. Preclinical studies have explored its potential in acute myeloid leukemia and hepatocellular carcinoma, often in combination with other immunotherapies or radiation, to enhance anti-tumor immune responses.

Other names: anti-TIM3anti-TIM-3anti-TIM 3

Targets

HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)

Beyond the preview

Go deeper on anti-TIM3 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-TIM3 antibody.

Explore the full profile